EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

OS ‐01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation Markers: A Pilot 12‐Week Clinical Trial

Alessandra Zonari iD, Lear E Brace, Luiza Brunelli Buhrer, Nathaniel H O Harder, Claire Harker, Adam B Aronson, Caitlyn N Tse, Carolina R Oliveira, Mariana Boroni, Juliana L Carvalho

Journal of Cosmetic Dermatology · 2025

DOI: 10.1111/jocd.70169 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Alessandra Zonari und 9 weiteren Autor:innen. Beteiligte Einrichtung: OneSkin, Inc., San Francisco, California, USA. Hauptthemen laut MEDLINE: Skin Aging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

As the body's largest organ, the skin plays a crucial role in defending against external stressors. Skin characteristics change with age, decreasing skin barrier integrity and compromising skin and body health. This study aimed to investigate the potential of a topical formulation containing OS‐01 (a.k.a. Peptide 14), a senotherapeutic peptide, to counteract age‐related skin changes and their systemic consequences.

Methods

A randomized, double‐blinded clinical trial involving 60 female volunteers aged 60–90 was conducted over 12 weeks. Participants received either an OS‐01 topical formulation or a commercially available moisturizer control formulation. Skin parameters, subjective perceptions, and circulating cytokine levels were assessed. Skin instrumental analysis included transepidermal water loss (TEWL), skin hydration, and pH measurements.

Results

Participants treated with the OS ‐01 topical formulation displayed significantly improved skin barrier function and hydration compared to the control group. Participant perceptions aligned with objective findings: after 12 weeks, 70% of participants in the OS ‐01 group noticed an improvement in general skin appearance versus 42% for the control group. The systemic levels of proinflammatory cytokines tended to normalize, with a significant decrease in IL‐8 in the blood analysis of participants from the OS ‐01 group. On the other hand, the control group demonstrated an increase in a few circulating cytokines, particularly TNF ‐ɑ and IFN ‐γ. Moreover, GlycanAge analysis measuring participants' biological age suggested the slowing of systemic aging in the group treated with the OS ‐01 topical formulation.

Conclusion

The study suggests that the OS‐01 formulation can impact skin health by improving the skin barrier function, potentially influencing systemic inflammation and biological age. In conclusion, the study supports that targeting skin health may contribute to better longevity outcomes, underscoring the skin's pivotal role in systemic aging and supporting an integrated approach to health management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin AgingHumansFemaleMiddle AgedPilot ProjectsAgedDouble-Blind MethodWater Loss, InsensibleAged, 80 and overAdministration, CutaneousSkinCytokinesBiomarkersInflammation

Stichwörter der Autor:innen

clinical trialinflammationsenescenceskin agingskin barrier function

Substanzen

CytokinesBiomarkers

Autor:innen und Institutionen

  • OneSkin, Inc., San Francisco, California, USA.
  • Skin Cancer and Reconstructive Surgery Center, Newport Beach, California, USA.
  • Bioinformatics and Computational Biology Lab, Brazilian National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.
  • Genomic Sciences and Biotechnology Program, Catholic University of Brasilia, Brasília, DF, Brazil.
  • Laboratory of Interdisciplinary Biosciences, Faculty of Medicine, University of Brasília, Brasília, DF, Brazil.

ORCID-Profile: Alessandra Zonari

Zitieren

APA

Zonari, A., Brace, L. E., Buhrer, L. B., Harder, N. H. O., Harker, C., Aronson, A. B., Tse, C. N., Oliveira, C. R., Boroni, M., & Carvalho, J. L. (2025). OS ‐01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation Markers: A Pilot 12‐Week Clinical Trial. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70169

Vancouver

Zonari A, Brace LE, Buhrer LB, Harder NHO, Harker C, Aronson AB, et al. OS ‐01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation Markers: A Pilot 12‐Week Clinical Trial. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70169

BibTeX
@article{Zonari2025,
  author = {Zonari, Alessandra and Brace, Lear E and Buhrer, Luiza Brunelli and Harder, Nathaniel H O and Harker, Claire and Aronson, Adam B and Tse, Caitlyn N and Oliveira, Carolina R and Boroni, Mariana and Carvalho, Juliana L},
  title = {OS ‐01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation Markers: A Pilot 12‐Week Clinical Trial},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  doi = {10.1111/jocd.70169}
}
Kostenlos starten →